↓ Skip to main content

Dove Medical Press

Article Metrics

CT-P13: design, development, and place in therapy

Overview of attention for article published in Drug Design, Development and Therapy, June 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

blogs
1 blog
twitter
1 tweeter

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
84 Mendeley
Title
CT-P13: design, development, and place in therapy
Published in
Drug Design, Development and Therapy, June 2017
DOI 10.2147/dddt.s109852
Pubmed ID
Authors

Tommaso Gabbani, Simona Deiana, Vito Annese

Abstract

The introduction of biological agents has revolutionized the management of many life-threatening and debilitating immune-mediated diseases. Because of the high cost of biological drugs and their patent expiration, the market has opened to biosimilar agents, copy versions of the originators, which can lead to reduced health care expenditure and increase treatment access worldwide. CT-P13 is the first biosimilar of infliximab (IFX) and has been approved for the same indications as its originator drug. It obtained regulatory approval by the European Medicines Agency in September 2013 and by the US Food and Drug Administration in April 2016. The Phase I and Phase III clinical trials conducted in ankylosing spondylitis and rheumatoid arthritis have demonstrated pharmacokinetic and efficacy equivalence with comparable safety and immunogenicity to IFX. For these reasons, the use of CT-P13 has been extrapolated also to inflammatory bowel disease. There have been some initial concerns regarding the use of CT-P13 in inflammatory bowel disease patients, because of the lack of randomized controlled trials. However, emerging real-world data have further confirmed the comparability between CT-P13 and its reference product in terms of efficacy, safety, and immunogenicity, in patients naïve to the anti-tumor necrosis factor alpha agents and after switching from IFX, and will be summarized in this review.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 84 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 14 17%
Student > Ph. D. Student 13 15%
Student > Master 11 13%
Researcher 9 11%
Other 6 7%
Other 13 15%
Unknown 18 21%
Readers by discipline Count As %
Medicine and Dentistry 27 32%
Pharmacology, Toxicology and Pharmaceutical Science 14 17%
Biochemistry, Genetics and Molecular Biology 4 5%
Nursing and Health Professions 4 5%
Social Sciences 3 4%
Other 9 11%
Unknown 23 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 July 2019.
All research outputs
#2,515,710
of 15,371,078 outputs
Outputs from Drug Design, Development and Therapy
#126
of 1,575 outputs
Outputs of similar age
#58,778
of 267,664 outputs
Outputs of similar age from Drug Design, Development and Therapy
#3
of 31 outputs
Altmetric has tracked 15,371,078 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,575 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,664 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.